By Hendra Lukman 
Stanford Medicine scientists have achieved a significant breakthrough in the fight against Type 1 diabetes, demonstrating in mouse models that a combined transplant of immunologically mismatched blood-forming stem cells and pancreatic islet cells can either entirely prevent the onset of the autoimmune disease or fully reverse it in established cases. This pioneering research, published online on November 18 in the Journal of Clinical Investigation, offers a beacon of hope for millions affected by this chronic condition and has broader implications for treating other autoimmune disorders and facilitating organ transplantation.
The study’s success hinges on the creation of a unique "hybrid immune system" within the recipient mice. This innovative approach circumvents the fundamental challenge of Type 1 diabetes: the body’s own immune system mistakenly identifies and destroys the insulin-producing islet cells in the pancreas. By carefully orchestrating a transplant of both blood stem cells and islet cells from a donor with a different genetic makeup, the researchers were able to retrain the recipient’s immune system, effectively making it tolerant to both the donor cells and its own pancreatic islets. Crucially, none of the treated mice developed graft-versus-host disease (GVHD), a dangerous complication where the transplanted immune cells attack the recipient’s healthy tissues. Over a six-month study period, these mice required no immunosuppressive drugs or insulin therapy, indicating a complete restoration of metabolic health.
A Groundbreaking Strategy: Building a Hybrid Immune System
Type 1 diabetes, a lifelong autoimmune disorder, is characterized by the immune system’s relentless assault on the beta cells within the pancreatic islets, leading to a severe deficiency in insulin production. This deficiency necessitates lifelong management with insulin injections and careful blood glucose monitoring to prevent life-threatening complications such as diabetic ketoacidosis, cardiovascular disease, nerve damage, and kidney failure. Current treatments focus on managing symptoms rather than addressing the root cause of the autoimmune destruction.
The Stanford team, led by Seung K. Kim, MD, PhD, the KM Mulberry Professor and a leading figure in developmental biology and endocrinology, built upon years of foundational research in stem cell transplantation and islet cell biology. Their previous work in 2022 demonstrated the potential of combining blood stem cell and islet cell transplants in a model of induced diabetes, where the disease was triggered by toxins rather than autoimmunity. In that study, a gentle pre-transplant conditioning regimen involving immune-targeting antibodies and low-dose radiation, followed by the dual transplant, successfully restored blood sugar control.
The latest research tackles a far more formidable challenge: preventing or curing Type 1 diabetes driven by spontaneous autoimmunity. This mirrors the human condition, where the immune system, for reasons not fully understood, begins to target its own healthy tissues. In this scenario, transplanted islets face a double threat: they are recognized as foreign by the recipient’s immune system, and that same immune system is already predisposed to attack islet cells.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," explained Dr. Kim, who also directs the Stanford Diabetes Research Center and the Northern California Breakthrough T1D Center of Excellence. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
The key to achieving this delicate balance lies in a refined pre-transplant conditioning protocol. The researchers discovered that by incorporating a medication commonly used to treat autoimmune diseases into the existing regimen—a tweak that appears deceptively simple—they could effectively prepare the mice for the dual transplant. This adjusted protocol, followed by the transplantation of blood stem cells and islet cells from an unrelated donor, resulted in the development of a hybrid immune system in 19 out of 19 treated mice, completely preventing the onset of Type 1 diabetes.
A Remarkable Cure and a Path Forward
The impact of this strategy was even more profound in a separate cohort of mice that already had established Type 1 diabetes. In these animals, nine out of nine experienced a complete cure following the combined blood stem cell and islet cell transplant. This suggests that the approach is not only preventative but also possesses significant therapeutic potential for individuals living with the disease.
The fact that the conditioning regimen utilizes antibodies, drugs, and low-dose radiation that are already part of standard clinical practice for blood stem cell transplantation makes the translation of this strategy to human trials a realistic and exciting prospect. The researchers are optimistic about the potential to move this approach towards clinical trials in humans with Type 1 diabetes in the near future.
Evolving from Kidney Tolerance to Hybrid Immunity
This groundbreaking work stands on the shoulders of decades of research by pioneers in immunology, notably the late Samuel Strober, MD, PhD, a distinguished professor of immunology and rheumatology at Stanford, and his colleagues, including study co-author Judith Shizuru, MD, PhD, a professor of medicine. Their earlier investigations demonstrated that bone marrow transplants from partially immunologically matched human donors could induce a hybrid immune system in recipients, leading to long-term acceptance of kidney transplants from the same donor. In some remarkable cases, these patients maintained stable kidney function for decades without the need for continuous immunosuppressive medications, a significant advancement in organ transplantation.
Blood stem cell transplants are a well-established treatment for hematologic malignancies like leukemia and lymphoma. However, in cancer therapy, these procedures typically involve high-dose chemotherapy and radiation to eradicate the patient’s existing blood and immune system, often leading to severe side effects. Dr. Shizuru and her team have been instrumental in developing safer, less intensive pre-conditioning strategies for non-cancerous conditions, aiming to reduce the risks associated with these transplants to a level acceptable for patients with chronic, non-life-threatening autoimmune diseases.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," stated Dr. Shizuru. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
The current study appears to have met this challenge. Dr. Kim elaborated on the mechanism: "Now we know that the donated blood stem cells re-educate the recipient animal’s immune system to not only accept the donated islets, but also not attack its healthy tissues, including islets. In turn, the donated blood stem cells and the immune system they produce learn to not attack the recipient’s tissues, and graft-versus-host disease can be avoided." This dual action—promoting tolerance to donor cells while suppressing autoimmunity—is the cornerstone of their success.
Navigating Future Hurdles and Broadening the Horizon
Despite the remarkable success in the mouse models, significant hurdles remain before this strategy can be widely implemented for human Type 1 diabetes treatment. A primary challenge is the limited availability of pancreatic islets, which are currently sourced exclusively from deceased donors. Furthermore, the blood stem cells must originate from the same donor as the islets, creating a logistical complexity. The quantity of islet cells obtainable from a single donor may also be insufficient to reverse established Type 1 diabetes in all cases.
The research team is actively exploring solutions to these limitations. One promising avenue involves generating large quantities of functional islet cells in the laboratory from pluripotent human stem cells, which could provide a more abundant and consistent supply. Researchers are also investigating methods to enhance the survival and function of transplanted donor islets after transplantation, maximizing their therapeutic effect.
Beyond Type 1 diabetes, the implications of this research extend to a wide spectrum of autoimmune diseases. Dr. Kim, Dr. Shizuru, and their collaborators believe that their refined pre-conditioning strategy could pave the way for stem cell transplants for conditions such as rheumatoid arthritis and lupus. It could also offer a less toxic alternative for treating non-cancerous blood disorders like sickle cell anemia, where current stem cell transplant methods are exceptionally harsh. Moreover, the approach holds promise for facilitating transplants of mismatched solid organs, reducing the reliance on lifelong immunosuppression and its associated side effects.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim emphasized. This sentiment underscores the transformative potential of their work, hinting at a future where autoimmune diseases and organ transplant rejection are managed with greater efficacy and fewer risks.
The research was supported by substantial funding from the National Institutes of Health, including grants T32 GM736543, R01 DK107507, R01 DK108817, U01 DK123743, P30 DK116074, and LAUNCH 1TL1DK139565-0. Additional support came from the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center. This collective investment highlights the scientific community’s commitment to unraveling complex diseases and developing innovative therapies. The successful translation of this research from bench to bedside could fundamentally alter the landscape of autoimmune disease management and regenerative medicine.
